Primary Outcomes

Description: eRVR was defined as undetectable Hepatitis C virus RNA at both Weeks 4 and 12. HCV RNA levels were measured by the Roche COBAS® TaqMan® HCV Test version 2.0 from the central laboratory.

Description: SVR24 was defined as undetectable RNA (Hepatitis C Virus [HCV] RNA Measure: Percentage of Participants With 24-week Sustained Virologic Response (SVR24)

Description: AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity; or was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.

Description: AE was defined as any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship. SAE was defined as a medical event that at any dose resulted in death, persistent or significant disability/incapacity, or; was life-threatening, an important medical event, or a congenital anomaly/birth defect; or required or prolonged hospitalization.

Secondary Outcomes

Description: RVR was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA Measure: Percentage of Participants With Rapid Virologic Response (RVR)

Description: cEVR was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA Measure: Percentage of Participants With Complete Early Virologic Response (cEVR)

Description: SVR12 was defined as undetectable RNA ie., Hepatitis C virus (HCV) RNA Measure: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)

Description: Non-structural protein 5A of HCV resistance associated polymorphism in GT-1a samples included M28L/T/V, Q30H, L31M, H54Y, H58C/D/N/P/Q, E62D and Y93C.

Description: Non-structural protein 5A of HCV resistance associated polymorphisms in GT-1b samples, included L28M/V, R30H/Q, L31M, Q54H/N/Y, P58A/Q/S, Q62E/K/N/R/S, A92T/V and Y93F/H.

Primary Outcomes

Description: patients who had undetectable HCV RNA levels at or after week 4. Viral relapse was defined as confirmed detectable HCV RNA levels during the post-treatment follow-up period in patients who had had undetectable HCV RNA levels at the end of treatment